Compare Quest Diagnostics Inc (DGX) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs GoPro Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while GoPro Inc trades at $0.7 (market cap $120.72M). The key difference: Quest Diagnostics Inc is far larger — about 188.9× GoPro Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| DGX | GPRO | |
|---|---|---|
Market Cap | $22.80B | $120.72M |
Sector | Health | Technology |
52-Week High | $216.02 | $2.88 |
52-Week Low | $166.42 | $0.64 |
Enterprise Value | $28.82B | $168.66M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
GoPro (GPRO) trades at $0.711, down 6.79% on the day, reflecting persistent operational challenges and negative investor sentiment. The stock exhibits a bearish technical outlook with consecutive earnings misses, declining revenue from $1.1B in 2022 to $652M in 2025, and negative net income margins. Recent news highlights a strategic review for potential sale or merger amid financial distress, including a $20M financing injection from CEO Nicholas Woodman in July 2026 to bolster liquidity.
The investment outlook remains highly speculative, with opportunities tied to a potential strategic transaction offering upside, but severe risks include going-concern warnings, cash burn, and competitive pressures. Analyst consensus is cautious, with only 21% buy ratings, emphasizing the binary nature of outcomes based on the company's ability to secure a lifeline or execute a turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
